Generative artificial intelligence firm Generate Biomedicines unveiled a novel protein discovery and development collaboration with Novartis AG on 24 September that it called part of an effort to ensure its technology helps as many patients as possible. Generate has previously partnered with Amgen, Inc. and is part of a pair of academic research alliances.
Generate Snares Novartis As Partner/Investor For Its AI/ML Approach
Like a previous alliance with Amgen, Generate will use its technology to discover and develop computationally designed therapeutic proteins against multiple undisclosed targets.
More from Strategy
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.